Skip to main content

ctDNA May Be a Biomarker for Postsurgery MRD Positivity and Relapse in Patients with NSCLC

Web Exclusives, FDA Approvals, News & Updates

Related Items

Immune Checkpoint Inhibitors Do Not Increase Mortality in Patients with Cancer and COVID-19
Articles
Web Exclusives, AACR
Impact of COVID-19 on Cancer Screening and How We Can Get Back on Track
By Sheryl A. Riley, RN, OCN, CMCN
Articles
Cancer Screening and COVID-19, Web Exclusives
Novel CAR T-Cell Therapy Shows Promise in Relapsed or Refractory Multiple Myeloma
By Charlie Dawson
Articles
Web Exclusives, Multiple Myeloma
Intratumoral Administration of INT230-6 Improves Drug Diffusion and Uptake into Cancer Cells in Patients with Advanced Solid Tumors
Articles
Web Exclusives, Emerging Therapies
Intratumoral Administration of INT230-6 Improves Drug Diffusion and Uptake into Cancer Cells in Patients with Advanced Solid Tumors
Articles
Web Exclusives, Emerging Therapies
A Call to Focus on Financial Toxicity and Quality of Life in Genitourinary Malignancies
Articles
Web Exclusives, ASCO
ctDNA May Be a Biomarker for Postsurgery MRD Positivity and Relapse in Patients with NSCLC
Articles
Web Exclusives, Lung Cancer, AACR
Luspatercept Effective in Patients with Lower-Risk Myelodysplastic Syndromes
Articles
FDA Approvals, News & Updates, Web Exclusives
FDA Grants Approval to Avapritinib for Patients with GIST
Articles
Web Exclusives, FDA Approvals, News & Updates
Regenerative Medicine Advanced Therapy Designation Granted to ADP-A2M4 for Synovial Sarcoma
Articles
FDA Approvals, News & Updates, Web Exclusives